Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 ConsortiumMieke Van Hemelrijck, Michael Fahey, Vincent J. Gnanapragasam et al.|European Urology|2018Cited by 93
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancerJody V. Vykoukal, Timothy C. Thompson, Johannes F. Fahrmann et al.|Nature Communications|2020Cited by 83
Androgen Regulation of 5α-Reductase Isoenzymes in Prostate Cancer: Implications for Prostate Cancer PreventionJin Li, Jeri Kim|PLoS ONE|2011Cited by 68
Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance InitiativeArveen Kalapara, Artitaya Lophatananon, Jan Verbeek et al.|European Urology Oncology|2019Cited by 37
Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance CohortsFrank‐Jan H. Drost, Nicole Benfante, Daan Nieboer et al.|European Urology|2019Cited by 24